D016159Chemicals & DrugsD12.776.157.687.650D12.776.260.820D12.776.624.776.775D12.776.660.720.650D12.776.744.84525890.913828Tumor Suppressor Protein p53Faculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson30289354Duan L, Perez RE, Maki CGCancer biology & therapyAlpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260.Cancer Biol Ther2018-10-05T00:00:002018Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a.31036564Duan L, Perez RE, Lai X, Chen L, Maki CGThe Journal of biological chemistryThe histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.J Biol Chem2019-04-29T00:00:002019The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.LeiDuanLei Duan349250Duan, LeiAssistant ProfessorMahboobehMahdaviniaMahboobeh Mahdavinia349419Mahdavinia, MahboobehAssistant ProfessorCarlMakiCarl Maki349531Maki, CarlProfessorSummerDewdneySummer Dewdney349599Dewdney, SummerAssistant ProfessorLotharBlatterLothar Blatter41.87432800000000-87.67059170000000349611Blatter, LotharProfessor6Assistant Professor4Professor33541735Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian CGynecologic oncologyMutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.Gynecol Oncol2021-02-02T00:00:002021Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Internal MedicineAnatomy and Cell BiologyRush University, Rush Medical Collegetrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor35058503Duan L, Perez RE, Calhoun S, Maki CGScientific reportsRBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.Sci Rep2022-01-20T00:00:002022RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.35658479Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KKJournal of clinical oncology : official journal of the American Society of Clinical OncologyTP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 10 01; 40(28):3289-3300.J Clin Oncol2022-06-03T00:00:002022TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.Obstetrics and Gynecologytrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessorPhysiology and Biophysicstrue1Assistant ProfessorAssistant Professor11.19460.0094966225research area of0.8831130.033961875subject area for